 Home > Active Ingredient News > Infection > Front Immunol: In severe COVID-19 patients, intravenous injection of large doses of immunoglobulin can reduce mortality.

Front Immunol: In severe COVID-19 patients, intravenous injection of large doses of immunoglobulin can reduce mortality.

 Last Update: 2021-09-10
 Source: Internet
 Author: User

Tags

scale calibration weight

graphite molecular structure

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Human immunoglobulin is a kind of passive immunotherapy .

Passive immunotherapy makes the patient from a state of reduced immunity or immunodeficiency, immune protection directly integrates toxins and kills bacteria or viruses

Background: The effective treatment of COVID-19 is still unclear

Methods: Based on a multi-center retrospective study to evaluate standard care, the effectiveness of IVIg administered at a total dose of 2 g/kg body weight within two weeks of onset

Results: A total of 26 patients received high-dose IVIg standard treatment, and 89 patients received only standard treatment

Figure 1 The dynamic changes of cytokines and inflammatory markers when severely ill hospitalized patients with the 2019 coronavirus (COVID-19) receive high-dose intravenous immunoglobulin (IVIg) treatment and standard care

Table 1 Demographic adjustment: control age and gender as covariates; complete adjustment: age, gender, complications, days of onset, baseline 7 scale categories,

Arbidol, LPV/r, IFN, RBV, OSV, antibiotics, antifungal drugs, traditional Chinese medicine, glucocorticoids, and low molecular weight heparin were used as covariates

Table 2 Subgroup and multivariate analysis of the effect of intravenous immunoglobulin (IVIg) treatment on 28-day mortality after inverse probability weighting (IPTW) adjustment

Population structure adjustment: control age and sex as covariates; complete adjustment: control age, sex, comorbidity, number of days of onset, baseline 7 scale categories,

Arbidol, LPV/r, IFN, RBV, OSV, antibiotics, antifungal drugs, traditional Chinese medicine, glucocorticoids, and low molecular weight heparin were used as covariates

Table 3 Kaplan-Meier curve of overall survival for severely ill hospitalized patients with 2019 coronavirus (COVID-19) receiving high-dose intravenous immunoglobulin (IVIg) treatment and/or standard care

Conclusion: Severe COVID-19 in the pathogenesis of 14 days, patients given large doses of IVIg and 28 days mortality has turned more pronounced in patients with no complications or early treatment

Severe COVID-19 in the pathogenesis of 14 days, patients given large doses of IVIg and 28 days mortality has turned more pronounced in patients with no complications or early treatment

Original source:

Cao W, Liu X, Hong K, Ma Z, et al, High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China.

Cao W, Liu X, Hong K, Ma Z, et al, High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China.
High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China .
Front Immunol 2021;12

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.